Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Capricor Therap (CAPR)

Capricor Therap (CAPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,400,342
  • Shares Outstanding, K 45,718
  • Annual Sales, $ 22,270 K
  • Annual Income, $ -40,470 K
  • EBIT $ -87 M
  • EBITDA $ -85 M
  • 60-Month Beta 0.37
  • Price/Sales 124.76
  • Price/Cash Flow N/A
  • Price/Book 15.21

Options Overview Details

View History
  • Implied Volatility 97.17% (-18.83%)
  • Historical Volatility 88.19%
  • IV Percentile 18%
  • IV Rank 8.72%
  • IV High 456.20% on 12/02/25
  • IV Low 62.85% on 01/22/26
  • Expected Move (DTE 10) 2.21 (6.19%)
  • Put/Call Vol Ratio 0.37
  • Today's Volume 3,107
  • Volume Avg (30-Day) 2,593
  • Put/Call OI Ratio 0.33
  • Today's Open Interest 86,002
  • Open Int (30-Day) 76,367
  • Expected Range 33.47 to 37.89

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.51
  • Number of Estimates 4
  • High Estimate -0.46
  • Low Estimate -0.55
  • Prior Year -0.16
  • Growth Rate Est. (year over year) -218.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.05 +58.14%
on 02/17/26
36.22 -3.73%
on 03/10/26
+10.24 (+41.58%)
since 02/10/26
3-Month
21.06 +65.57%
on 01/29/26
36.22 -3.73%
on 03/10/26
+6.20 (+21.63%)
since 12/10/25
52-Week
4.30 +710.93%
on 11/25/25
40.37 -13.62%
on 12/03/25
+22.53 (+182.58%)
since 03/10/25

Most Recent Stories

More News
Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA

Deramiocel has the potential to become the first therapy to address both skeletal and cardiac manifestations of Duchenne muscular dystrophy BLA supported by positive pivotal HOPE-3 Phase 3 results,...

CAPR : 35.85 (+17.04%)
Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12

– Company to Host Conference Call on March 12, 2026, at 4:30 p.m. ET – SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics  (NASDAQ: CAPR), a biotechnology company developing...

CAPR : 35.85 (+17.04%)
Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference

Late-breaking presentation at MDA to feature Phase 3 HOPE-3 results supporting Deramiocel in Duchenne muscular dystrophy HOPE-3 clinical study report (CSR) submitted to the U.S. Food and Drug Administration...

CAPR : 35.85 (+17.04%)
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data

FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review process Company expects to submit updates to the BLA in February 2026 to support continued FDA review SAN DIEGO,...

CAPR : 35.85 (+17.04%)
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy

– Webinar to be held Wednesday, December 17, 2025, at 1:00 p.m. ET – SAN DIEGO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing...

CAPR : 35.85 (+17.04%)
Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock

SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the pricing...

CAPR : 35.85 (+17.04%)
Capricor Therapeutics Announces Proposed Public Offering of Common Stock

SAN DIEGO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the commencement...

CAPR : 35.85 (+17.04%)
This ‘Strong Buy’ Penny Stock Just More Than Quadrupled on Clinical Trial Results. Should You Buy It Here?

Capricorn Therapeutics stock soared after the biotech firm announced positive deramiocel Phase 3 trial results. But CAPR shares still have major risks tied to them heading into 2026.

CAPR : 35.85 (+17.04%)
Wall Street pulls near its all-time high

U.S. stocks rose near their record levels

NVDA : 185.23 (+1.41%)
$SPX : 6,800.66 (+0.07%)
DLTR : 117.99 (+1.85%)
MDB : 268.54 (-1.18%)
AEO : 19.24 (+4.17%)
$IUXX : 25,022.42 (+0.22%)
M : 18.63 (+3.62%)
SIG : 94.00 (+2.61%)
MSFT : 405.60 (-0.93%)
PG : 155.53 (+0.20%)
$DOWI : 47,836.94 (+0.20%)
MCHP : 66.08 (+1.66%)
Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy

Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key secondary cardiac endpoint (LVEF), both achieving statistical significance (p=0.03...

CAPR : 35.85 (+17.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 70%. The market has entered overbought territory.

See More Share

Business Summary

Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based...

See More

Key Turning Points

3rd Resistance Point 34.13
2nd Resistance Point 32.77
1st Resistance Point 31.70
Last Price 36.13
1st Support Level 29.27
2nd Support Level 27.91
3rd Support Level 26.84

See More

52-Week High 40.37
Last Price 36.13
Fibonacci 61.8% 26.59
Fibonacci 50% 22.33
Fibonacci 38.2% 18.08
52-Week Low 4.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar